Meet the 2025 Dare2Scale Cohorts – PRAEVA Biotech
33 founders from 18 companies across Bulgaria and the Western Balkans are joining Dare2Scale 2025 — united in one program to scale bold ideas and grow thriving businesses.
Meet PRAEVA Biotech who develops clinically integrated biotech solutions for dental medicine. Its innovation, Equiome™, targets biofilm control to deliver predictable and long-lasting results in complex treatments through a microbiome-preserving approach.
PRAEVA is grounded in science, built on clinical expertise, and designed with scalable potential across medicine.
Tell us how your story began. What was the inflection point that made you realize this could become a serious business, not just an idea?
It began in 2016 with a clinical question that struck me during a freshman lecture I was attending as part of my postgraduate specialization: could we control biofilm by targeting its enzymatic triggers—without disrupting the oral microbiome? I knew even then this was more than a research topic. It was a fundamental gap in modern dentistry, and I committed years to investigating it alongside my clinical practice and my academic growth.
The turning point came in 2020, when the world paused—and I finally had time to focus. That led to the development of Equiome™: a complex of activated fatty acids that inhibits biofilm formation at its source, while preserving microbial balance.
When the data confirmed it worked, the decision was no longer personal. I knew I had a responsibility to make it accessible—to protect clinical outcomes sensitive to biofilm, and to support the long-term success of modern dental treatment and prevention. That’s when Praeva became inevitable.
Share a little-known fact about your industry, product, or market that would surprise most people.
A little-known fact about dentistry is that biofilm is the leading cause of both dental disease and treatment complications—yet most products still rely on broadly destructive antibacterial strategies.
Other fields—gut, skin, oncology—have already shifted toward microbiome-preserving care. But dentistry hasn’t caught up. Antibacterials remain the default, even in high-risk areas like implantology and orthodontics, where inadequate biofilm control and dysbiosis often lead to inflammation, treatment failure, and costly re-interventions.
Praeva Biotech introduces a new category of biofilm control: an enzyme-targeted, microbiome-respecting approach based on selective biology. It’s precision prevention, built for the next generation of dental care.
Five years from now, what headline would you love to read about your company?
“Free Fatty Acids Replace Antibiotics in Aftercare: Praeva’s Biotech Breakthrough Sets New Standard Across Medicine”
Subheadline:
From dental implants to dermatology and gynecology, Praeva’s enzyme-targeting fatty acid complex is redefining how clinicians manage post-treatment healing.